Lat­est on re­ver­ber­a­tions of abor­tion pill rul­ing; Biotech ven­ture fund­ing dips; No­vo Nordisk dives in­to di­a­betes cell ther­a­py; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Be sure to check our web­site over the week­end if you’re in­ter­est­ed in can­cer re­search — Nicole De­Feud­is and Kather­ine Lewin are in Or­lan­do re­port­ing the lat­est up­date out of the AACR con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER